Week in Review: Shanghai ChemPartner, a China CRO/CMO, Completes Reverse Merger

Deals and Financings   Shanghai ChemPartner, a CRO/CMO, closed its reverse merger with Quantum Hi-Tech China Biological at an undisclosed valuation;  YiChang HEC ChangJiang Pharm raised $400 million from Blackstone Group via a convertible bond offering representing a 15% share in HEC; The Buck Institute for Research on Aging, Insilico and Juvenescence joined together to form Napa Therapeutics, a company using AI to develop an anti-aging drug; Haisco Pharma invested $10 million in Pneuma Respiratory in return for China rights to Pneumahaler™, a novel asthma/COPD inhaler; Crown Biosciences, a global CRO, in-licensed rights to translational mouse platforms developed by Shanghai Model Organisms Center ; Company News Adlai Nortye, a Hangzhou biopharma, opened a Boston site that will be the company's target validation and translational medicine center; Trials and Approvals Sirnaomics of Maryland was approved to start US trials of its anti-cancer/anti-fibrosis siRNA therapeutic in patients with advanced cholangiocarcinoma; Sihuan Pharma started a China Phase II trial of pirotinib, a novel EGFR oncology treatment, in patients with non-small cell lung cancer; CANbridge Life Sciences, a Beijing in-licensing company, will begin a China Phase Ib/III clinical study of a drug for esophageal squamous cell cancer; Stock Watch Loncar launched its China BioPharma ETF, a fund that gives international investors access to a diversified portfolio of 28 China-based innovative biopharmas. Stock Symbols: (SZE: 300149) (HK: 1558) (NYSE: BX) (SHZ: 002653) (HK: 0460) (NSDQ: CHNA) Share this with colleagues: // //